I-Mab Biopharma Partners with MorphoSys on Cancer Investigational Medicine

November 30, 2017

Responsive image

SHANGHAI, Dec. 1, 2017 /PRNewswire/ — I-Mab Biopharma (I-Mab) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that they have entered into an exclusive regional licensing agreement to develop and commercialize MOR202 in China, Taiwan, Hong Kong and…

Category: Precious Metals